Amphastar Pharmaceuticals Inc ( (AMPH) ) has released its Q3 earnings. Here is a breakdown of the information Amphastar Pharmaceuticals Inc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Amphastar Pharmaceuticals Inc., a biopharmaceutical company specializing in complex generic and proprietary injectable, inhalation, and intranasal products, recently reported its financial results for the third quarter of 2025. The company is known for its focus on technically challenging products and its commitment to expanding patient access to affordable therapies.
In the third quarter of 2025, Amphastar Pharmaceuticals reported net revenues of $191.8 million, with a GAAP net income of $17.4 million or $0.37 per share. The adjusted non-GAAP net income stood at $44.7 million or $0.93 per share. The company highlighted significant revenue growth from BAQSIMI®, which saw a 14% increase compared to the same period last year, and the successful launch of its iron sucrose injection.
Key financial metrics for the quarter included a slight increase in total net revenues by $626,000 compared to the previous year, despite challenges such as decreased sales in some products like epinephrine and glucagon due to pricing pressures and competition. The company’s strategic initiatives, including an exclusive licensing agreement with Nanjing Anji Biotechnology, aim to bolster its proprietary pipeline and target high-growth markets in oncology and ophthalmology.
Amphastar’s management remains optimistic about the future, emphasizing sustained commercial momentum and strategic pipeline expansion. The recent FDA approval and launch of new products, coupled with ongoing marketing efforts, are expected to drive long-term growth and value across the company’s portfolio.